Key Takeaways: 

• Quality From Day One: Regulatory compliance is embedded into every stage of development and manufacturing to support product approval.

• Consistent Quality, Everywhere: Our unified global quality system delivers high standards of compliance for all products manufactured at our facilities in the U.S., Europe, and Asia.

• A Proven Track Record: A history of successful regulatory inspections and industry recognition demonstrate our continuous commitment to quality.

• Partners on the Regulatory Path: From IND to BLA to MAA, we provide tailored regulatory strategy and support to help partners access the global market faster and with greater confidence.

At AGC Biologics, we believe that quality is not a checkpoint at the end of the development process. It is the foundation every step builds upon. For the patients who will ultimately receive the biologics and cell and gene therapies we help bring to market, that commitment is everything.

The Importance of regulatory and quality compliance. Why does it matter so much in protein biologics and cell and gene therapy manufacturing? 

The path from clinical trials to commercialization is long and demanding. For our partners developing biologics, cell and gene therapies, and other advanced modalities, every decision, from early process development through to commercial manufacturing, carries regulatory weight. A misstep in quality compliance can delay a regulatory approval by months or years, or worse, deny patients access to a therapy they urgently need.

That responsibility is not lost on us. Our integrated quality systems are designed to ensure that each product leaving our facilities meets the stringent standards required by global health authorities, including the FDA, EMA, PMDA, DMA, PEI, HC, TFDA, MFDS, and ANVISA. Compliance is not just an obligation; it is how we protect patients and advance precision medicine.

How does AGC Biologics build quality into the manufacturing process from the start?

Our approach to cGMP manufacturing begins with a thorough understanding of each client's product and target market. From the earliest stages of process development, our teams conduct detailed risk assessments, design scalable processes, and build in the flexibility needed to adapt as regulatory guidance evolves.

Our quality assurance teams continuously monitor new and changing global regulations, updating internal procedures to maintain a constant state of inspection readiness across our global network of sites. Expert teams spanning process development, technical transfer, production, and analytical sciences work in close collaboration to ensure quality is embedded into every stage. When we begin work on an early-phase project for a partner client, we are always thinking “how can this project scale as it advances AND address needed CMC and regulatory milestones along the way?”

From a technical perspective, we leverage process analytical technology (PAT) to generate real-time data during production. By monitoring critical process parameters and quality attributes in-line, our scientists can optimize manufacturing conditions as needed to maintain product quality and yield. We also continue to invest in innovative, single-use technology that enhances consistency across scales while reducing the risk of product carryover, an important consideration for complex, high-value therapies.

What does a globally integrated quality system mean for our partners?

Consistency and knowledge sharing across our network of facilities in the U.S., Europe, and Asia are strategic advantages that directly benefit our clients. Learnings from regulatory inspections at one site inform best practices across all others, strengthening our collective state of compliance.

We also work side-by-side with our partners to provide comprehensive documentation supporting regulatory filings, including INDs, BLAs, NDAs, and MAAs, and tailor our regulatory strategy to each product and its target markets. With full-pipeline support, we help clients move through clinical development and into commercial production with confidence.

How does AGC Biologics' track record demonstrate a commitment to quality and compliance? 

With more than three decades of cGMP manufacturing experience, our team has supported more than 30 commercial product approvals for partners and accumulated a track record of over 100 successful regulatory inspections by global health authorities. In 2025 alone, our sites successfully completed nine inspections from seven different agencies worldwide, reinforcing our continuous state of compliance.

Industry recognition reflects this commitment as well. In April, AGC Biologics was selected as the 2026 recipient of the Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance, honoring our exemplary regulatory strategy, robust quality systems, and compliance execution.

How does continuous improvement keep our quality system ahead of the curve? 

The regulatory landscape is constantly evolving, so it is essential that our quality management system adapts along with it. Our culture of continuous improvement means we are always refining our processes, enhancing our analytical capabilities, and investing in platforms from cell line development to advanced cell and gene therapy technologies to meet the demands of the next generation of therapeutics.

For our partners, that means working with a CDMO whose quality systems grow alongside the science. Whether a product is entering its first clinical trial or approaching commercial approval, our integrated quality and regulatory framework is built to carry it forward.

_____________________________ 

Ready to advance your program with a trusted partner in regulatory and quality compliance? 

Connect With Our Team Today